PCRX — Pacira BioSciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1396814 ·
Last close
$36.48
Market Cap
$1.46B
52W High
$36.67
52W Low
$18.80
ADV30
2,230,807
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 176,653,000 | 139,420,000 | 16,542,000 | 28,521,000 | 1,202,639,000 | 246,957,000 | 490,318,000 |
| Jun 2026 | 192,399,000 | 148,235,000 | 11,861,000 | 4,653,000 | 1,243,978,000 | 205,875,000 | 572,002,000 |
| Mar 2026 | 177,376,000 | 140,963,000 | 4,625,000 | 2,916,000 | 1,208,534,000 | 144,306,000 | 554,641,000 |
| Dec 2025 | 196,873,000 | 156,574,000 | -10,921,000 | 1,637,000 | 1,264,917,000 | 158,545,000 | 571,806,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$187,663,000
Investing CF
$94,147,000
Financing CF
$-376,176,000
CapEx
$-8,148,000
Dividends Paid
—
Buybacks
$-148,334,000
EPS Diluted TTM
$0.35
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-191,753,000
Inventory
$134,575,000
Receivables
$132,420,000
ST Investments
$45,156,000
EBIT TTM
$30,952,000
Pretax Income TTM
$17,648,000
Interest Exp TTM
$13,304,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$743,300,992
EBITDA
$133,044,000
Free Cash Flow
$198,565,872
Enterprise Value
$1,505,351,424
Total Cash
$295,576,992
Total Debt
$340,280,000
Shares Out
39,912,226
Trailing EPS
$0.93
Book Value
$17.85
ROE
5.2%
ROA
2.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 726,411,000 | 19,191,000 | 7,034,000 | 1,264,917,000 | 571,806,000 | 693,111,000 | 151,994,000 |
| Dec 2024 | 700,966,000 | 89,872,000 | -99,560,000 | 1,553,516,000 | 775,168,000 | 778,348,000 | 189,389,000 |
| Dec 2023 | 674,978,000 | 87,675,000 | 41,955,000 | 1,574,386,000 | 704,256,000 | 870,130,000 | 154,649,000 |
| Dec 2022 | 666,823,000 | 60,024,000 | 15,909,000 | 1,681,200,000 | 906,190,000 | 775,010,000 | 145,274,000 |
TTM Snapshot
Revenues TTM
$746,164,000
NetIncome TTM
$14,638,000
OpCashFlow TTM
—
Assets (Latest)
$1,243,978,000
Forward EPS
$3.46
Max Pain — expiry 2027-01-15
max pain strike: $35.00 · spot: $36.48 · call oi: 1,519 · put oi: 319
Expected Move to 2027-01-15:
±$0.55
(1.51%) —
implied range
$35.93 –
$37.03
· ATM straddle on $37.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QURE | uniQure N.V. | $1.46B | $20.78 | — |
| URGN | UroGen Pharma Ltd. | $1.47B | $29.87 | — |
| KRSA | Korsana Biosciences, Inc. | $1.48B | $32.50 | — |
| RAPP | Rapport Therapeutics, Inc. | $1.41B | $23.76 | — |
| DMRA | Damora Therapeutics, Inc. | $1.40B | $22.56 | — |
News headlines (Yahoo Finance, 1h cache)
Viatris Completes Acquisition of Pacira BioSciences
2026-11-17 13:50 · Yahoo
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
2026-10-30 12:40 · Yahoo
Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth
2026-10-29 13:00 · Yahoo
Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal Framing
2026-10-23 16:13 · Yahoo
Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says
2026-10-09 15:23 · Yahoo
Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus
2026-10-09 06:09 · Yahoo
Viatris (VTRS) Stock May Be Below Fair Value Despite A $1.65B Deal
2026-11-08 01:15 · Yahoo
Viatris Inc. Q3 2026 Earnings Call Summary
2026-11-05 22:41 · Yahoo
Viatris Reports Third-Quarter 2026 Financial Results
2026-11-05 11:59 · Yahoo
Viatris Announces Quarterly Dividend
2026-11-04 11:59 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.